Your session is about to expire
← Back to Search
Pembrolizumab for Recurrent Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new drug to see if it is safe and effective for treating NSCLC that has returned after radiation therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of breathing problems without a known cause.You have a current, active Hepatitis B or C infection.You have had radiation treatment in the past 6 months for the same area that would be treated again.You have lung cancer and have had radiation treatment in the chest area before. If the cancer comes back in or near the same area, you may not need another biopsy, but your doctor will decide.You need to use oxygen all the time.You had your condition get worse while taking a specific type of medication that helps the immune system fight cancer.The size of the treatment area must be less than 250 cc, and you have not received more than 74 Gy of radiation in the past.You had cancer before, but it was treated and there is no sign of it coming back in the last 2 years.You are allergic to Pembrolizumab or similar medications.You have experienced severe lung inflammation after receiving radiation therapy.You have had a tissue or organ transplant from another person.You have cancer that has spread outside of the chest, including to the brain, or you have fluid around the lungs or heart caused by cancer.You need to have enough platelets and white blood cells in your blood.You have a severe autoimmune disease that needs strong medication, except if you have vitiligo, resolved childhood asthma/atopy, stable hypothyroidism, or Sjorgen's syndrome.Your bilirubin levels in the blood need to be within a certain range.Your kidney function is good, and your creatinine levels are within a certain range.You have a history of being infected with Human Immunodeficiency Virus (HIV).You have a weakened immune system or have taken strong medications that lower your body's ability to fight off infections within the past week.You are able to perform daily activities without any difficulty or with slight restriction.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab undergone the FDA's approval process?
"While there is some data indicating that Pembrolizumab is safe, it did not receive a higher score because there is no evidence yet of the efficacy."
What other similar tests has Pembrolizumab been a part of in the past?
"Pembrolizumab is being studied in 1000 different clinical trials, 122 of which are currently active. Of the active trials, many are based in Houston but there are 36034 total locations for these medical studies."
Does this study have open enrollment at the moment?
"Currently, this clinical trial is not enrolling patients. This study was first posted on January 18th, 2017 and was last edited on November 1st, 2022. However, there are 3038 other trials related to lung cancer currently recruiting participants and 1000 studies involving Pembrolizumab that are actively admitting patients."
What are the most common illnesses that Pembrolizumab is prescribed for?
"Pembrolizumab can be used to target and treat malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Share this study with friends
Copy Link
Messenger